ISA 61 VG佐剂增强单核细胞增生李斯特氏菌灭活疫苗的保护性免疫应答

ISA 61 VG adjuvant enhances protective immune response of Listeria monocytogenes inactivated vaccine

摘要:

单核细胞增生李斯特氏菌 (Listeria monocytogenes，Lm) 是重要的人兽共患李斯特氏菌病的致病菌，疫苗免疫是预防该病原菌感染的有效手段之一。本研究研制了添加矿物油佐剂MontanideTM ISA 61 VG的新型灭活细菌疫苗，并对其安全性和免疫应答特性进行了研究。结果表明，ISA 61 VG佐剂疫苗具有较好的安全性；诱导小鼠产生的抗李斯特氏菌溶血素O抗体滴度以及IgG2a/IgG1比值显著高于无佐剂免疫组；在致死剂量Lm攻毒下，能对小鼠提供100%的免疫保护。因此，ISA 61VG佐剂能显著增强灭活疫苗诱导宿主产生体液免疫和细胞免疫应答的能力，从而提高灭活疫苗的保护性免疫应答作用，是预防人和动物Lm感染的潜在疫苗候选株。

Abstract:

Listeria monocytogenes (Lm) is zoonotic pathogen that can cause listeriosis, and vaccine is one of the effective methods to prevent this pathogen infection. In this study, we developed a novel vaccine that is a mixture of inactivated bacteria and MontanideTM ISA 61 VG, a mineral oil adjuvant, and evaluated the safety and immune response characteristics of this vaccine. The mice immunized with the ISA 61 VG adjuvant had high safety, and it could induce significantly higher titer of anti-listeriolysin O (LLO) antibody and higher value of IgG2a/IgG1 ratio compared with the group without the adjuvant. In particular, it could provide 100% immune protection against lethal doses of Lm challenge in mice. In summary, ISA 61VG adjuvant significantly enhanced the ability of inactivated listeria vaccine to induce humoral and cellular immune responses, thereby enhanced the protective immune response in the host, and it is a potential vaccine candidate for the prevention of Lm infection in humans and animals.